ZYBERNO
Stock Report
Updated Aug 24, 2026

Mesoblast Limited (MEOBF)

Healthcare • OTC

$1.89

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
13.0/100
POOR BUSINESS
Mesoblast Limited (MEOBF) scores 13/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.20x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (0.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Mesoblast Limited (MEOBF) stock report — Zyberno Score 13/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.89
Market Cap:$2.42B

Valuation Multiples (3)

P/B Ratio:4.05x
P/S Ratio:49.69x
Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$2.38B
Ev Ebitda Ratio:371.79x

Price Action & Momentum (3)

Momentum Percentile:84 / 100
% of 52-Week High:57.1%
B. Profitability Assessment

Margin Analysis (1)

Ebitda Margin:13.1%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):4.4%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.99x
Quick Ratio:1.78x
Cash Ratio:1.57x

Leverage Analysis (3)

Debt To Equity Ttm:0.20x
Debt-to-Equity Ratio:0.20x
Debt To Ebitda:19.05x

Coverage Ratios (2)

Interest Coverage Ratio:0.00x
Times Interest Earned:0.00

Capital Structure (4)

Working Capital:101,724,000.00
Cash And Cash Equivalents:161,551,000.00
Long Term Debt:$67.74M
Net Debt:-$39.66M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $48.69M
Linear Growth: 4.4%
📊 Click to view full MEOBF Revenue analysis & methodology →
Cost Of Revenue Ttm:$7.60M

Profitability Breakdown (2)

$0.00$0.00

Bottom Line Performance (3)

-$102.14M
Income Before Tax:$0.00
Ebitda Ttm:6,400,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:-$6.45M
Interest Expense:14,191,000.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:13.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$784.68M
Current Assets:$204.35M
Ppe Net:1,702,000.00
Goodwill:0.00
Intangible Assets:$571.83M

Liability Structure (4)

Total Liabilities:187,241,000.00
Current Liabilities:102,626,000.00
Long Term Debt:$67.74M
Short Term Debt:$54.16M

Equity & Capital (3)

Equity:$597.44M
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:14,866,000.00
Inventory:21,664,000.00
Accounts Payable:19,082,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$49.95M-$50.38M

Investment Activities (1)

Investing Cash Flow:-$203.00K

Financing Activities (3)

Financing Cash Flow:$40.30M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.08

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.04
Operating Cash Flow Per Share:-$0.04

Book Value & Capital (2)

Book Value Per Share:$0.47
Cash Per Share:0.13

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.06x
Working Capital Turnover Ttm:0.48x

Receivables Management (2)

Receivables Turnover Ttm:3.27x
Days Sales Outstanding Ttm:111.45

Inventory Management (2)

Inventory Turnover Ttm:0.35x
Days Inventory Outstanding Ttm:1,039.89

Payables & Cash Cycle (2)

Days Payable Outstanding:915.96
Cash Conversion Cycle:235.39
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):4.4%
C. Company Profile & Context

Corporate Information (6)

Symbol:MEOBF
Company Name:Mesoblast Limited
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:OTC
Country:Australia

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:1.28B
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-24 09:34:16 UTC
Data Timestamp:2026-08-24T07:44:24.544417
Scroll to Top